TOP TEN perturbations for NP_775739 (Homo sapiens)

Organism: Homo sapiens
Gene: NP_775739
Selected probe(set): 225997_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NP_775739 (225997_at) across 6593 perturbations tested by GENEVESTIGATOR:

expO kidney cancer study 1 (neoplasm, malignant; primary) / expO kidney cancer study 1 (granular cell carcinoma; primary)

Relative Expression (log2-ratio):-4.679969
Number of Samples:2 / 4
Experimental expO kidney cancer study 1 (neoplasm, malignant; primary)
Primary tumor tissue samples obtained from the kidney of patients with malignant neoplasm.
Control expO kidney cancer study 1 (granular cell carcinoma; primary)
Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma.

brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample

Relative Expression (log2-ratio):3.4844503
Number of Samples:2 / 3
Experimental brefeldin A study 1 (0.5ug/ml; p53HCT116)
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated p53HCT116 cell sample
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

expO kidney cancer study 1 (granular cell carcinoma; primary) / expO kidney cancer study 1 (clear cell adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):3.3969688
Number of Samples:4 / 207
Experimental expO kidney cancer study 1 (granular cell carcinoma; primary)
Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma.
Control expO kidney cancer study 1 (clear cell adenocarcinoma, NOS; primary)
Primary tumor tissue samples obtained from the kidney of patients with clear cell adenocarcinoma (NOS).

expO kidney cancer study 1 (renal cell carcinoma, NOS; primary) / expO kidney cancer study 1 (granular cell carcinoma; primary)

Relative Expression (log2-ratio):-3.3388395
Number of Samples:5 / 4
Experimental expO kidney cancer study 1 (renal cell carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the kidney of patients with renal cell carcinoma (NOS).
Control expO kidney cancer study 1 (granular cell carcinoma; primary)
Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma.

ovarian tumor study 17 / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):3.1696358
Number of Samples:9 / 10
Experimental ovarian tumor study 17
Human epithelial tumor cell samples from the ovary of patients with primary clear cell carcinoma. Samples were derived by laser capture microdissection (LCM).
Control normal ovarian surface epithelial cell sample
Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue from donors with non-cancerous, benign gynecological diseases.

expO kidney cancer study 1 (clear cell adenocarcinoma, NOS; metastatic) / expO kidney cancer study 1 (granular cell carcinoma; primary)

Relative Expression (log2-ratio):-3.0904522
Number of Samples:3 / 4
Experimental expO kidney cancer study 1 (clear cell adenocarcinoma, NOS; metastatic)
Metastatic tumor tissue obtained from a patient with primary clear cell adenocarcinoma (NOS) of the kidney.
Control expO kidney cancer study 1 (granular cell carcinoma; primary)
Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma.

expO kidney cancer study 1 (renal cell carcinoma, chromophobe type; primary) / expO kidney cancer study 1 (neoplasm, malignant; primary)

Relative Expression (log2-ratio):3.026102
Number of Samples:18 / 2
Experimental expO kidney cancer study 1 (renal cell carcinoma, chromophobe type; primary)
Primary tumor tissue samples obtained from the kidney of patients with renal cell carcinoma, chromophobe type.
Control expO kidney cancer study 1 (neoplasm, malignant; primary)
Primary tumor tissue samples obtained from the kidney of patients with malignant neoplasm.

expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary) / expO kidney cancer study 1 (granular cell carcinoma; primary)

Relative Expression (log2-ratio):-2.9428186
Number of Samples:3 / 4
Experimental expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary)
Primary tumor tissue samples obtained from the kidney of patients with renal cell carcinoma, sarcomatoid.
Control expO kidney cancer study 1 (granular cell carcinoma; primary)
Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma.

expO kidney cancer study 1 (papillary adenocarcinoma, NOS; primary) / expO kidney cancer study 1 (granular cell carcinoma; primary)

Relative Expression (log2-ratio):-2.925084
Number of Samples:22 / 4
Experimental expO kidney cancer study 1 (papillary adenocarcinoma, NOS; primary)
Primary tumor tissue samples obtained from the kidney of patients with papillary adenocarcinoma (NOS).
Control expO kidney cancer study 1 (granular cell carcinoma; primary)
Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma.

tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample

Relative Expression (log2-ratio):2.6047363
Number of Samples:3 / 3
Experimental tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-))
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 DICER1(-/-) cell sample
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.